Document Detail


A functional-structural model to understand cardiac autonomic nervous system (ANS) dysregulation in affective illness and to elucidate the ANS effects of antidepressive treatment.
MedLine Citation:
PMID:  14766337     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Numerous studies provide evidence that major depression (MD) is associated with certain disorders of cardiac autonomic nervous system (ANS) function, in particular, with an autonomic neurocardiac imbalance characterized by a low cardiovagal modulation, a raised sympathetic nerve activity and a high resting heart rate. We assume that such MD-associated cardiac ANS disorders are mainly caused by functional-structural abnormalities within the central autonomic network (CAN), in particular, by well-defined abnormalities of hypothalamic structures in MD. In view of the well-known association between an autonomic neurocardiac imbalance and the risk for cardiac arrhythmias, we assume that MD-associated cardiac ANS disorders are at least partly responsible for the high cardiovascular mortality risk in MD. It is, however, still unclear whether antidepressive treatment will lower the risk for cardiovascular complications in MD. There is convincing evidence that a successful antidepressive treatment with electroconvulsive therapy, cognitive behavioral therapy, or pharmacotherapy with primarily non-antimuscarinergic antidepressants can improve an initially disturbed cardiac ANS function in MD. These studies correspond well to our findings that treatment with both, nefazodone or reboxetine, can induce a reduction of central sympathetic nerve activity and an increase of the initially lowered cardiovagal modulation depending on the improvement of depressive symptoms after treatment. Since both effects occured obviously independent from the primarily serotonergic or noradrenergic action of the antidepressants, our findings suggest the existence of a generally supraordinate and uniform mechanism underlying the ANS effects of antidepressive treatment with drugs inhibiting serotonin- or noradrenaline reuptake.
Authors:
Marcus W Agelink; A Klimke; J Cordes; D Sanner; I Kavuk; R Malessa; E Klieser; B Baumann
Related Documents :
1512337 - Effects of converting enzyme inhibition on baroreflex sensitivity in patients with myoc...
7771587 - Physiological correlates of vagal nerve innervation in lower vertebrates.
17013267 - Central neuroaxis blockade and coronary circulation.
1967557 - Alpha-adrenergic mechanisms in myocardial ischemia.
23065097 - Mri quantification of left ventricular function in microinfarct versus large infarct in...
15026867 - Dyslipoproteinemia and peripheral arterial occlusive disease.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  European journal of medical research     Volume:  9     ISSN:  0949-2321     ISO Abbreviation:  Eur. J. Med. Res.     Publication Date:  2004 Jan 
Date Detail:
Created Date:  2004-02-09     Completed Date:  2004-03-11     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  9517857     Medline TA:  Eur J Med Res     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  37-50     Citation Subset:  IM    
Affiliation:
Department of Psychiatry, Psychotherapy and Psychosomatic Medicine, Ruhr-University of Bochum, Germany. mw.agelink.md@t-online.de
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antidepressive Agents / therapeutic use*
Autonomic Nervous System Diseases / complications*,  drug therapy*,  physiopathology
Depressive Disorder / complications,  drug therapy*
Heart / innervation*
Humans
Chemical
Reg. No./Substance:
0/Antidepressive Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Hemorrhoidectomy: indications and risks.
Next Document:  The molecular basis of intellectual disability: novel genes with naturally occurring mutations causi...